Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 34

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 34
---
 October 2025 Securities Purchase Agreement is subject to a mutual option of the Company and certain October 2025 Investors and satisfaction of customary closing conditions. Description of Securities See “ Description of Capital Stock” for a description of the Series E Preferred Stock. Impact on Stockholders of Approval or Disapproval of this Proposal If this proposal is approved, existing stockholders will suffer dilution in ownership interests and voting rights as a result of the issuance of shares of Common Stock upon the conversion of the shares of Series E Preferred Stock. Assuming the issuance of all shares of Common Stock upon conversion of the Series E Preferred Stock, the October 2025 Investors would own approximately 2.3million shares of Common Stock, assuming conversion at the initial conversion price of $4.1625 per share of the Series E Preferred Stock. Such shares would constitute approximately 10.1% of the then -CommonStock after the issuance of such shares. Because the conversion price of the Series E Preferred Stock 18

may be adjusted, the number of shares that will actually be issued may be more or less than such number of shares, as further described under “Potential Adjustments” above. The ownership interest of the existing stockholders (other than the October 2025 Investors) would be correspondingly reduced. The number of shares of Common Stock described above does not give effect to (i) the potential future issuance of additional shares of Common Stock due to potential future anti -dilutionadjustments on the Series E Preferred Stock, (ii) the potential future issuance of shares of Common Stock pursuant to the Permitted Equity Lines (as defined in the October 2025 Securities Purchase Agreement), (iii) the potential future issuance of shares of Common Stock pursuant to other outstanding options and warrants, or (iv) any other potential future issuances of Common Stock. The sale into the public market of these shares also could materially and adversely affect the market price of the Common Stock. If this proposal is approved, the issuance of the Common Stock could have an anti -takeovereffect because such issuance would make it more difficult for, or discourage an attempt by, a party to obtain control of the Company by tender offer or other means. The issuance of the Common Stock will increase the number of shares entitled to vote, increase the number of votes required to approve a change of control of the Company, and dilute the interest of a party attempting to obtain control of the Company. The Board does not have any current knowledge of any effort by any third party to accumulate the Company’s securities